May 22 2024Massachusetts General Hospital In new research, investigators at Massachusetts General Hospital show that the 100-year-old Bacillus Calmette-Guérin vaccine, originally developed to prevent tuberculosis, protects individuals with type 1 diabetes from severe COVID-19 disease and other infectious diseases.
Denise Faustman, MD, PhD, senior author, director of the Immunobiology Laboratory at MGH and Associate Professor of Medicine at Harvard Medical School The MGH Phase II and Phase III clinical trials testing BCG differed from other BCG trials in important ways. Instead of receiving one dose of BCG, participants received five or six doses of a particularly potent strain of BCG vaccine. The US participants were followed for a total of 36 months instead of weeks or months. "We know that in people who are naïve to BCG vaccine, the off-target effects can take at least two years to achieve full protection," said Faustman.
Related StoriesDuring the earlier Phase II trial when the virus was more lethal but less transmissible, the BCG vaccine's efficacy was 92%, comparable to the efficacy of the Pfizer and Moderna COVID-19 vaccines in healthy adults.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: medical_xpress - 🏆 101. / 51 Read more »